A Novel Standard for Systematic Reporting of Neuroblastoma Surgery: The International Neuroblastoma Surgical Report Form (INSRF)

A Joint Initiative by the Pediatric Oncological Cooperative Groups SIOPEN, COG**, and GPOH****

Lucas E. Matthyssens, MD, FEBPS,✉ Jed G. Nuchtern, MD,† Cees P. Van De Ven, MD,‡ Hany O. S. Gabra, MD, FRCS(Paed),§ Kristin Bjornland, MD, PhD,¶ Sabine Irtan, MD,|| Jakob Stenman, MD, PhD,** Luca Pio, MD,†† Kate M. Cross, MD,‡‡ Stefano Avanzini, MD,§§ Alessandro Inserra, MD, PhD,¶¶ Javier Gomez Chacon, MD,|||| Patrizia Dall'igna, MD,*** Dietrich Von Schweinitz, MD, PhD,††† Keith Holmes, MD,‡‡‡ Jorg Fuchs, MD, PhD,§§§ Roly Squire, MD,¶¶¶ Dominique Valteau-Couanet, MD, PhD,|||||| Julie R. Park, MD,**** Angelika Eggert, MD,†††† Paul D. Losty, MD, FRCSI, FRCS(Eng), FRCS(Ed) FRCS(Paed) FEBPS,‡‡‡‡ Michael P. La Quaglia, MD, PhD,§§§§ and Sabine Sarnacki, MD, PhD¶¶¶¶, on behalf of the Surgical and Medical Committees of SIOPEN*, COG** and GPOH****

Objective: To create the first structured surgical report form for NBL with international consensus, to permit standardized documentation of all NBL-related surgical procedures and their outcomes.

Summary of Background Data: NBL, the most common extracranial solid malignant tumor in children, covers a wide spectrum of tumors with significant differences in anatomical localization, organ or vessel involvement, and tumor biology. Complete surgical resection of the primary tumor is an important part of NBL treatment, but maybe hazardous, prone to complications and its role in high-risk disease remains debated. Various surgical guidelines exist within the protocols of the different cooperative groups, although there is no standardized operative report form to document the surgical treatment of NBL.

Methods: After analyzing the treatment protocols of the SIOP Europe International Neuroblastoma Study Group, Children's Oncology Group, and Gesellschaft fuer Paediatrische Onkologie und Haematologie – German Association of Pediatric Oncology and Haematology pediatric cooperative groups, important variables were defined to completely describe surgical biopsy and resection of NBL and their outcomes. All variables were discussed within the Surgical Committees of SIOP Europe International Neuroblastoma Study Group, Children's Oncology Group, and Gesellschaft fuer Paediatrische Onkologie und Haematologie – German Association of Pediatric Oncology and Haematology. Thereafter, joint meetings were organized to obtain intercontinental consensus.

Results: The ''International Neuroblastoma Surgical Report Form'' provides a structured reporting tool for all NBL surgery, in every anatomical region, documenting all Image Defined Risk Factors and structures involved, with obligatory reporting of intraoperative and 30 day-postoperative complications.

From the *Department of Gastrointestinal and Pediatric Surgery, Princess Elisabeth Children's Hospital, Ghent University Hospital, Ghent, Belgium; †Division of Pediatric Surgery, Michael E. DeBakey Department of Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas; ‡Department of Pediatric Surgery, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands; §Department of Pediatric Surgery, The Great North Children Hospital, Newcastle University Teaching Hospitals, Newcastle Upon Tyne, United Kingdom; ¶Department of Gastrointestinal and Pediatric Surgery, Oslo University Hospital and University of Oslo, Oslo, Norway; ||Department of Pediatric Surgery, Hôpital d'enfants Armand-Trousseau, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France; **Department of Pediatric Surgery and Urology, Astrid Lindgren Children's Hospital, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; ††Department of Visceral and Urological Pediatric Surgery, Hôpital Universitaire Robert-Debré, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France; ‡‡Specialist Neonatal and Pediatric Surgery, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom; §§Pediatric Surgery Unit, Istituto Giannina Gaslini, Genoa, Italy; ¶¶Department of Surgery, Ospedale Pediatrico Bambino Gesu', Roma, Italy; ||||Department of Pediatric Surgery, Hospital Universitario y Politécnico La Fé, Valencia, Spain; ***Division of Pediatric Surgery, Department of Women's and Children's Health, University of Padova, Padova, Italia; †††Department of Pediatric Surgery, Dr. von Hauner Children's Hospital, University Hospital, LMU, Munich, Germany; ‡‡‡Department of Paediatric Surgery, St George's Hospital, London, United Kingdom§§§ Department of Pediatric Surgery and Pediatric Urology, University Hospital Tuebingen, Tuebingen, Germany; ¶¶¶Department of Paediatric Surgery, Leeds Children's Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; ||||||Department of Pediatric and Adolescent Oncology, Institut Gustave Roussy, Villejuif, France; ****Department of Pediatrics, Seattle Children's Hospital, University of Washington School of Medicine, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; ††††Department of Paediatric Oncology & Hematology, Charité University Medicine Berlin, Germany; ‡‡‡‡Academic Department of Pediatric Surgery, Division of Child Health, Alder Hey Children's Hospital, NHS Foundation Trust, University of Liverpool, Liverpool, United Kingdom; §§§§Pediatric Surgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical School, New York, New York; and ¶¶¶¶Department of Pediatric Surgery, Université de Paris, Hôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris, Paris, France.

✉lucas.matthyssens@uzgent.be.

*SIOPEN: SIOP Europe International Neuroblastoma Study Group.

**COG: Children's Oncology Group.

***GPOH: Gesellschaft fuer Paediatrische Onkologie und Haematologie – German Association of Pediatric Oncology and Haematology.

Part of this paper was presented at the 50th Congress of the International Society of Pediatric Oncology (SIOP) and the International Society for Pediatric Surgical Oncology (IPSO), November 16, 2018, in Kyoto, Japan.

The authors declare no conflicts of interest and received no funding.

ISSN: 0003-4932/20/27503-e575

Conclusion: The International Neuroblastoma Surgical Report Form is the first universal form for the structured and uniform reporting of NBL-related surgical procedures and their outcomes, aiming to facilitate the postoperative communication, treatment planning and analysis of surgical treatment of NBL.

Keywords: biopsy, Clavien-Dindo classification, complication, high-risk, neuroblastoma, operation, outcome, postoperative, quality, reporting, resection, standardization, surgery, tumor

(*Ann Surg* 2022;275:e575–e585)

Neuroblastoma (NBL), an embryonal sympathetic nervous system tumor, is the most common cancer in infants and the most common extracranial solid malignant tumor in children,[1–4] with an overall age-standardized incidence rate of 10.2–10.9 cases per million children in the USA and Europe, respectively.[2,3] NBL accounts for 6% of all childhood cancers[1] and 12%–15% of cancer-related deaths under the age of 15 years.[3,5]

NBL has a broad spectrum of clinical behavior that correlates with a number of clinical and biological features.[6] After international consensus, NBL is treated multimodally, according to the pretreatment International NBL Risk Group (INRG) classification system.[6]

This system identifies 4 risk categories (very low-, low-, intermediate-, and high-risk) taking into account the tumor stage, age at diagnosis, histology, grade, Neuroblastoma Myc (MYCN) oncogene status, chromosomal aberrations, and tumor cell ploidy.[6] To uniformly stage NBL before the initiation of treatment, the INRG-Staging-System was developed, based upon tumor imaging and on the absence or presence of preoperative "Image-Defined Risk Factors" (IDRFs).[7] These IDRFs describe the various locations where NBL may occur and the vital structures (organs, vascular, and neural structures) that may be involved by the tumor.[8]

As NBL originates from developmental anomalies of the neural crest, there is a wide spectrum of locations where the primary tumor may occur, related to the sympathetic nervous system anatomy.[3] The anatomical distribution of NBL can be described by compartmental classification (Fig. 1)[4] and most primary tumors arise in the abdominal compartment (adrenal gland 48%, extra-adrenal retroperitoneum 25%). The thoracic location of NBL is less frequent accounting for 16%–20%, and the cervical and pelvic compartments account for 3% to 5% of NBL, respectively.[4] Recent



FIGURE 1. Radiogenomics classification of neuroblastoma by anatomical localization of the primary tumor: compartmental versus sympathetic chain classification with respective genomic profile distribution.[4] (with permission of the authors).

studies suggest that the sympathetic anatomical location of NBL may also be relevant as a prognostic factor.[4]

Local control of the primary tumor by complete surgical resection is an important part of NBL treatment. The role of surgical resection in high-risk NBL however remains debated as it is difficult to study, due to the relative rarity of NBL, its different localizations, heterogenous presentations[4] and internationally varying treatment protocols, incorporating postoperative radiation therapy to aid in local control. Especially for high-risk NBL, divergent results have been reported on the role, extent, and timing of surgical resection.[9–11] In addition, the reporting of surgical treatment of NBL is not standardized and may vary considerably.

As the surgical reporting of a postoperative residual primary tumor may influence postoperative irradiation planning in future high-risk NBL treatment protocols, the documentation of NBL surgery and its immediate outcomes must be optimized.

Improving the quality of surgical reporting will also facilitate the analysis of the role, extent, and timing of surgical treatment in NBL. Therefore we aimed to develop a uniform, structured report form to document every NBL-related surgical procedure.

METHODS

A working party group within the Surgical Committee of SIOP Europe International Neuroblastoma Study Group (SIOPEN), under the joint leadership of the first and the last author, started in 2014 with the NBL-Surgical Report Form-project. After the approval of the members of the Surgical Committees of the Children's Oncology Group (COG) and of the German Association of Paediatric Oncology and Haematology (GPOH), the surgical guidelines in the different study protocols of SIOPEN, COG, and GPOH were analyzed to identify the variables needed to completely describe the mode and impact of surgical interventions (biopsy and resection) for NBL, and the outcomes of the surgical intervention. All crucial variables describing the timing, mode, management of IDRFs and the operative results were listed, defined and discussed within the working group of the SIOPEN Surgical Committee.

Thereafter, a first draft of a structured report form was developed, in different steps, discussing each step within the SIOPEN Surgical Committee, until consensus was reached on the Neuroblastoma Surgical Report Form (NSRF). In parallel, the same action was performed within the Surgical Committees of COG and GPOH. Over the years, several joint meetings were organized to discuss and standardize the NSRF draft together with the members of all 3 Surgical Committees to obtain intercontinental consensus. After its conception, the International Neuroblastoma Surgical Report Form (INSRF) was tested and used in clinical practice by the members of the core working party group, confirming its feasibility and completeness,

RESULTS

The INSRF is the first universal report form to document every NBL-related surgical procedure (biopsy and resection) and contains 5 sections on 5 pages, see Fig. 2. The first 4 sections are ideally completed by the surgeon immediately after the surgical intervention.

The first section of the INSRF includes coded patient and treatment protocol details.

The second section involves the type, timing, and date of the intervention, the surgical approach (open or minimally invasive surgery) and the extent of the biopsy or resection, including 4 options, defined with international consensus: ''*complete resection*;'' ''*minimal residue*'' (defined as ''less than 5 cubic centimeter of tumor remaining''); ''*incomplete resection*'' (defined as ''5 or more cubic centimeter residue'') or ''*other*,'' for which detailed information is then fully requested.

The localisation of the primary tumor is uniformly reported by the indication of the anatomical compartment(s) (cervical, cervicothoracic, thoracic, thoraco-abdominal, abdominal/pelvic). Surgical metastatic sites are reported by organ. Preoperative plan discussion at a multidisciplinary tumor board is recorded.

In addition, section 2 incorporates the description of all preoperative post-chemotherapy IDRFs, according to the definitions of terms to describe relationships between primary tumor and vital structures stated in the INRG Guidelines for Imaging and Staging of Neuroblastic Tumors.[8]

The surgical findings are documented in the third section of the INSRF. Here, the surgeon indicates and documents all organs and structures involved, and their individual intraoperative management, by the use of agreed-upon and well-defined surgical terminology. To document vessel involvement, the surgeon can differentiate between 2 types: ''*adherence*'' is defined as vessel involvement of <50% of the circumference, and ''*encasement*'' as 50%–100% of the vessel circumference.[12] If a blood vessel was injured, the surgeon specifies how this injury was managed during the surgical intervention and if macroscopic residual tumor remained at this location or not. The side of the vessel is indicated and in case of bilateral involvement, detailed specifications per side can be added as free text. In the same fashion, organ involvement is to be reported. When appropriate, the side of involvement is documented and in case of bilateral involvement detailed specifications per side can be added as free text. The type of organ involvement is stated as ''*adherence*'' (defined as close contact between tumor and organ but with a distinct plane of dissection) or ''*infiltration*'' (no distinct dissection plane, necessitating partial (even minimal) organ resection). The surgeon then documents how the organ involvement was treated by the use of 1 out of 3 options (''*no organ resection*'' – ''*partial organ resection*,'' or ''*complete organ resection*'') and whether macroscopic residual tumor was left or not. Liver involvement is described using the segmental classification, as described by Couinaud.[13]

The fourth section of the INSRF documents all intraoperative complications and the management/intervention(s) performed to solve the complication, with enough free text space to add detailed specifications or remarks.

Possible intraoperative deviations from the preoperative plan discussed at a multidisciplinary tumor board can be indicated and described in detail.

The last section of the INSRF is to be completed by the surgeon 1 month after the operation. This final part describes the postoperative complications, related to the surgery, during the first 30 days after the operation, see Fig. 2. To standardize the reporting of postoperative outcomes, the Clavien-Dindo classification was adopted, with space added in the form for free text specifications.[14,15] In addition, the surgeon is expected to report any unscheduled delay of the postoperative chemotherapy regimen(s) due to the surgery or its complications within the first 30 days after the surgical intervention and to specify how long this delay lasted (in days).[11]

DISCUSSION

We created the first INSRF with intercontinental consensus for the structured and uniform reporting of all NBL-related surgical procedures and their outcomes. Due to the various locations of NBL and frequent encasement or infiltration of vital structures and organs, the surgical treatment of NBL may be highly challenging with important operative morbidity and even mortality.[9,16] In localized NBL, the impact of surgical resection is well established and

International Neuroblastoma Surgical Report Form (INSRF)

Form to be filled out by the surgeon for every surgical procedure

Patient Initials: .....
ID system: COG / GPOH / SIOPEN
ID number: .....

DATE OF INTERVENTION
. . / . . / . . . . (DD/MM/YYYY)

PROTOCOL

- ☐ SIOPEN HRNBL2
- ☐ LINES
- ☐ NBL 2015
- ☐ COG PROTOCOL:
- ☐ .....

☐ BIOPSY

- ☐ Diagnosis
- ☐ Relapse / Progression
- ☐ Other: ...

- ☐ Needle core biopsy 14-16 Ga, US guided
- ☐ Open
- ☐ MIS : Laparoscopic / Thoracoscopic
- ☐ Endoscopic: ...
- ☐ Other: .....

☐ RESECTION

Timing

- ☐ Diagnosis
- ☐ During Induction (primary site resection)
- ☐ After Induction chemotherapy
- ☐ After High dose chemotherapy
- ☐ Relapse/progression
- ☐ Other

Open

- ☐ Laparotomy
- ☐ Thoracophrenolaparotomy
- ☐ Thoracotomy
- ☐ Clamshell
- ☐ Trap-door
- ☐ Transmanubrial
- ☐ Cervical incision

MIS

- ☐ Laparoscopy
- ☐ Thoracoscopy
- ☐ Both

Extent of resection

- ☐ Complete excision
- ☐ Minimal Residual Tumor < 5 cm^3 *
- ☐ Incomplete excision > 5 cm^3 *
- ☐ Other: ...

*** 5 cm^3 equals the content of a 5 ml syringe, a spherical tumor measuring 2.1 cm in one dimension, or a cubic tumor measuring 1.7 cm on one side.**

TUMOR LOCALISATION (A-F) & PREOPERATIVE IDRF (POST-CHEMOTHERAPY):

EXTENT OF PRIMARY TUMOR – IDRF	Yes	No	N.A.
A Ipsilateral tumor extension within two body compartments			
A.1 Neck-chest			
A.2 Chest-abdomen			
A.3 Abdomen-pelvis			
B Neck			
B.1 Tumor encasing carotid and/or vertebral artery and/or internal jugular vein			
B.2 Tumor extending to base of skull			
B.3 Tumor compressing the trachea			
C Cervico-thoracic junction			
C.1 Tumor encasing brachial plexus roots			
C.2 Tumor encasing subclavian vessels and/or vertebral and/or carotid artery			
C.3 Tumor compressing the trachea			
D Thorax			
D.1 Tumor encasing the aorta and/or major branches			
D.2 Tumor compressing the trachea and/or principal bronchi			
D.3 Lower mediastinal tumor, infiltrating the costo-vertebral junction between T9 and T12			
E Thoraco-abdominal			
E.1 Tumor encasing the aorta and/or vena cava			
F Abdomen/pelvis			
F.1 Tumor infiltrating the porta hepatis (liver hilum) and/or hepatoduodenal ligament			
F.2 Tumor encasing branches of the superior mesenteric artery at the mesenteric root			
F.3 Tumor encasing the origin of the celiac axis and/or of the superior mesenteric artery			
F.4 Tumor invading one or both renal pedicles			
F.5 Tumor encasing the aorta and/or vena cava			
F.6 Tumor encasing the iliac vessels			
F.7 Tumor crossing the sciatic notch			
G Intraspinal tumor extension whatever location provided that:			
G.1 More than one third of the spinal canal in the axial plane is invaded and/or the perimedullary leptomeningeal spaces are not visible and/or the spinal cord signal is abnormal			
H Infiltration of adjacent organs/structures			
H.1 Pericardium			
H.2 Diaphragm			
H.3 Kidney			
H.4 Liver			
H.5 Duodeno-pancreatic block			
H.6 Mesentery			
H.7 Other organ (H.8) considered to be of similar significance			
H.8 Organ (H.7) infiltrated:			

☐ SURGICAL METASTATIC SITE

- ☐ Brain
- ☐ Liver
- ☐ Lung
- ☐ Lymph nodes
- ☐ Other: ...

☐ Pre-operative plan discussed at a Multidisciplinary Tumor Board (MTB): ☐ **NO** / ☐ **YES**

FIGURE 2. The International Neuroblastoma Surgical Report Form (INSRF): paper form on 5 pages.

International Neuroblastoma Surgical Report Form (INSRF)

VASCULAR INVOLVEMENT	**Side***	**Type** (SURGICAL FINDING):**	**SURGICAL INJURY**	**PEROPERATIVE SOLUTION**	**Macroscopic residual tumor**
☐ Carotid artery	☐ Left ☐ Right ☐ Bilateral	☐ Adherence ☐ Encasement	☐ No ☐ Yes	☐ Repair ☐ Reconstruction ☐ Ligation	☐ No ☐ Yes
☐ Internal Jugular vein	☐ Left ☐ Right ☐ Bilateral	☐ Adherence ☐ Encasement	☐ No ☐ Yes	☐ Repair ☐ Reconstruction ☐ Ligation	☐ No ☐ Yes
☐ Subclavian/innominate artery	☐ Left ☐ Right ☐ Bilateral	☐ Adherence ☐ Encasement	☐ No ☐ Yes	☐ Repair ☐ Reconstruction ☐ Ligation	☐ No ☐ Yes
☐ Subclavian/innominate vein	☐ Left ☐ Right ☐ Bilateral	☐ Adherence ☐ Encasement	☐ No ☐ Yes	☐ Repair ☐ Reconstruction ☐ Ligation	☐ No ☐ Yes
☐ Superior vena cava	☐ Left ☐ Right ☐ Bilateral	☐ Adherence ☐ Encasement	☐ No ☐ Yes	☐ Repair ☐ Reconstruction ☐ Ligation	☐ No ☐ Yes
☐ Pulmonary artery	☐ Left ☐ Right ☐ Bilateral	☐ Adherence ☐ Encasement	☐ No ☐ Yes	☐ Repair ☐ Reconstruction ☐ Ligation	☐ No ☐ Yes
☐ Thoracic Aorta		☐ Adherence ☐ Encasement	☐ No ☐ Yes	☐ Repair ☐ Reconstruction ☐ Ligation	☐ No ☐ Yes
☐ Abdominal Aorta		☐ Adherence ☐ Encasement	☐ No ☐ Yes	☐ Repair ☐ Reconstruction ☐ Ligation	☐ No ☐ Yes
☐ Portal vein		☐ Adherence ☐ Encasement	☐ No ☐ Yes ☐	☐ Repair ☐ Reconstruction ☐ Ligation	☐ No ☐ Yes
☐ Celiac axis		☐ Adherence ☐ Encasement	☐ No ☐ Yes	☐ Repair ☐ Reconstruction ☐ Ligation	☐ No ☐ Yes
☐ Superior mesenteric artery		☐ Adherence ☐ Encasement	☐ No ☐ Yes	☐ Repair ☐ Reconstruction ☐ Ligation	☐ No ☐ Yes
☐ Renal artery	☐ Left ☐ Right ☐ Bilateral	☐ Adherence ☐ Encasement	☐ No ☐ Yes	☐ Repair ☐ Reconstruction ☐ Ligation ☐ Nephrectomy	☐ No ☐ Yes
☐ Renal vein	☐ Left ☐ Right ☐ Bilateral	☐ Adherence ☐ Encasement	☐ No ☐ Yes	☐ Repair ☐ Reconstruction ☐ Ligation ☐ Nephrectomy	☐ No ☐ Yes
☐ Inferior mesenteric artery		☐ Adherence ☐ Encasement	☐ No ☐ Yes	☐ Repair ☐ Reconstruction ☐ Ligation	☐ No ☐ Yes
☐ Iliac artery	☐ Left ☐ Right ☐ Bilateral	☐ Adherence ☐ Encasement	☐ No ☐ Yes	☐ Repair ☐ Reconstruction ☐ Ligation	☐ No ☐ Yes
☐ Iliac vein	☐ Left ☐ Right ☐ Bilateral	☐ Adherence ☐ Encasement	☐ No ☐ Yes	☐ Repair ☐ Reconstruction ☐ Ligation	☐ No ☐ Yes
☐ Inferior vena cava		☐ Adherence ☐ Encasement	☐ No ☐ Yes	☐ Repair ☐ Reconstruction ☐ Ligation	☐ No ☐ Yes
☐ Other: …	☐ Left ☐ Right ☐ Bilateral	☐ Adherence ☐ Encasement	☐ No ☐ Yes	☐ Repair ☐ Reconstruction ☐ Ligation	☐ No ☐ Yes

*** Please tick the involved side. If Bilateral, please specify surgical details per side clearly as free text**

**** Type of vessel involvement: <50% of circumference of the vessel = Adherence ; 50-100% of circumference of the vessel = Encasement.**
(Brisse HJ et al., Guidelines for Imaging & Staging of Neuroblastic Tumors: Consensus Report from the INRG Project. Radiology. 2011;261:243-57)

FIGURE 2. (Continued).

International Neuroblastoma Surgical Report Form (INSRF)

ORGAN INVOLVEMENT*	Type*** (SURGICAL FINDING)	SURGICAL TREATMENT of organ involved	Macroscopic residual tumor
☐ Skull base	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection:	☐ No ☐ Yes
☐ Thyroid	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection	☐ No ☐ Yes
☐ Trachea ☐ Main bronchus: ☐ Right* ☐ Left*	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection	☐ No ☐ Yes
☐ Lung: ☐ Right* ☐ Left* ☐ Bilateral*	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection:	☐ No ☐ Yes
☐ Heart	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection:	☐ No ☐ Yes
☐ Pericardium	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection:	☐ No ☐ Yes
☐ Diaphragm: ☐ Right* ☐ Left* ☐ Bilateral*	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection	☐ No ☐ Yes
☐ Kidney: ☐ Right* ☐ Left* ☐ Bilateral*	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection: ..... ☐ Complete organ resection	☐ No ☐ Yes
☐ Liver, specify segment(s) **:	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection:	☐ No ☐ Yes
☐ Gallbladder	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection: ..... ☐ Complete organ resection	☐ No ☐ Yes
☐ Pancreas	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection:	☐ No ☐ Yes
☐ Spleen	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection: ..... ☐ Complete organ resection	☐ No ☐ Yes
☐ Mesentery	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection:	☐ No ☐ Yes
☐ Bowel: specify ☐ duodenum ☐ small bowel ☐ colorectum	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection: ..... ☐ Complete organ resection:	☐ No ☐ Yes
☐ Bladder	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection:	☐ No ☐ Yes
☐ Ureter: ☐ Right* ☐ Left* ☐ Bilateral*	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection:	☐ No ☐ Yes
☐ Uterus	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection: ..... ☐ Complete organ resection	☐ No ☐ Yes
☐ Ovary: ☐ Right* ☐ Left* ☐ Bilateral*	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial resection of organ: ..... ☐ Complete resection of organ	☐ No ☐ Yes
☐ Costovertebral junction T9-12	☐ Intraspinal extension	☐ Partial resection through foramen ☐ Complete resection up to level of foramen	☐ No ☐ Yes
☐ Other level spinal foramen: Specify level:	☐ Intraspinal extension	☐ Partial resection through foramen ☐ Complete resection up to level of foramen	☐ No ☐ Yes
☐ Other: ..... Please specify:	☐ Adherence ☐ Infiltration	☐ No organ resection ☐ Partial organ resection: ..... ☐ Complete organ resection	☐ No ☐ Yes

*** Please tick the involved side. If Bilateral, please specify surgical details per side clearly as free text**
**** Liver segmental anatomy according to Couinaud (**Couinaud C. Liver Anatomy: Portal (and Suprahepatic) or Biliary Segmentation. Dig Surg 1999;16:459-67)
***** Type of involvement: In close contact with clear dissection plane: Adherence; No clear dissection plane: Infiltration**

FIGURE 2. (Continued).

International Neuroblastoma Surgical Report Form (INSRF)

INTRAOPERATIVE COMPLICATIONS	INTERVENTION	EXTRA SPECIFICATIONS
Intraoperative hemorrhage >30% blood volume ☐ NO ☐ YES, please specify location/cause:	☐ Stable circulation after transfusion a/o fluids ☐ Requiring inotropic support ☐ Circulatory arrest – successful resuscitation ☐ Peroperative death	
Hypovolemia ☐ NO ☐ YES, please specify location/cause:	☐ Stable circulation after transfusion a/o fluids ☐ Requiring inotropic support ☐ Circulatory arrest – successful resuscitation ☐ Peroperative death	
Fluid overload with need for diuretics and/or O2 ☐ NO ☐ YES, please specify cause:.....	☐ Requiring diuretics only ☐ Requiring inotropic support ☐ Circulatory arrest – successful resuscitation ☐ Peroperative death	
Pulmonary embolus ☐ NO ☐ YES	☐ Stable circulation after transfusion a/o fluids ☐ Requiring inotropic support ☐ Circulatory arrest – successful resuscitation ☐ Peroperative death	
Vascular injury (→ see previous Table) ☐ NO ☐ YES		
Nerve injury ☐ NO ☐ YES, please specify cause:	☐ No intervention ☐ Primary repair ☐ Reconstruction	Nerve(s) affected:
Unplanned injury/removal of an organ other than the affected adrenal ☐ NO ☐ YES, please specify cause:	☐ Partial nephrectomy: ☐ Right / ☐ Left ☐ Total nephrectomy: ☐ Right / ☐ Left ☐ Partial hepatectomy: segment:..... ☐ Partial splenectomy ☐ Total splenectomy ☐ Partial colectomy ☐ Partial colectomy with colostomy ☐ Small bowel resection ☐ Small bowel resection with enterostomy ☐ Contralateral adrenal (non affected) ☐ Partial pancreatectomy ☐ Other:	
Renal ischemia: ☐ NO ☐ YES, please specify extent: ☐ Partial, resolved before end of operation ☐ Partial, persistent at the end of surgery ☐ Total, resolved before end of operation ☐ Total, persistent at the end of surgery	☐ No intervention ☐ Renal vessel repair ☐ Renal vessel reconstruction ☐ Partial resection ☐ Total resection	Reason: ☐ Vascular injury ☐ Vascular spasm ☐ Hypovolemia ☐ Other: .....
Peroperative death ☐ NO ☐ YES, please specify cause: ☐ Bleeding ☐ Other cause: ..... ☐ Unknown cause	☐ Autopsy performed ☐ YES ☐ NO	Specify if known
Other:		

Were there any intra-operative DEVIATIONS from the Preoperative plan discussed at Multidisciplinary Tumor Board (MTB)?
☐ **NO** / ☐ **YES** → Please specify: .....
Did this lead to intra- or post-operative complications? ☐ **NO** / ☐ **YES** → Please specify: .....

FIGURE 2. (Continued).

International Neuroblastoma Surgical Report Form (INSRF)

POSTOPERATIVE COMPLICATIONS *up till Postoperative Day 30*	CLAVIEN-DINDO CLASSIFICATION (see next page)	SPECIFY
Postoperative bleeding: ☐ NO / ☐ YES, specify cause:	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	
Hypovolemia requiring inotropic support: ☐ NO / ☐ YES	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	
Fluid overload requiring diuretics +/- O2: ☐ NO / ☐ YES	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	
Systemic inflammatory response syndrome (SIRS) requiring intensive care > 72h: ☐ NO / ☐YES	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	
Stroke: ☐ NO / ☐ YES	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	
Vascular spinal cord injury: ☐ NO / ☐ YES	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	
Renal atrophy (ischemia): ☐ **Right / ☐ Left** ☐ NO ☐ YES, specify: ☐ Partial ischemia ☐ Total ischemia	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	Diagnosis: ☐ US ☐ CT ☐ Nuclear scan
Renal dysfunction: ☐ NO / ☐ YES, specify:	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	
Bladder dysfunction: ☐ NO / ☐ YES, specify:	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	
Hepatic dysfunction: ☐ NO / ☐ YES, specify:	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	
Pulmonary dysfunction: ☐ NO / ☐ YES, specify:	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	
Postop stenosis of vascular structures : ☐ NO / ☐ YES:	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	
Infection: ☐ NO ☐ YES : ☐ Fever >48h postop eci, AB administ ☐ Pneumonia ☐ Urinary tract ☐ Wound ☐ Intravenous access line ☐ Other, please specify:	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	Specify on postop day…
Adrenal insufficiency : ☐ NO / ☐ YES, specify	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	
Intestinal obstruction > 7 days ☐ NO ☐ YES, specify: ☐ Paralytic Ileus ☐ Mechanical Obstruction	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	
Wound dehiscence ☐ NO ☐ YES, specify location & postop day	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	
Chylous leak – Chest : ☐ NO / ☐ YES	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	
Chylous leak – Abdomen: ☐ NO / ☐ YES	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	
Unplanned ICU admission: ☐ NO ☐ YES, specify	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	Postop day:: Cause: Treatment:
Unplanned return to operating theater ☐ NO ☐ YES, specify	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	Postop day:: Cause: Treatment::
Diarrhea 30 days postop (without infectious cause) ☐ NO ☐ YES	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	
Motor Nerve dysfunction: ☐ NO ☐ YES, please specify cause:	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	Nerve(s) affected:
Sensory Nerve dysfunction: ☐ NO ☐ YES, please specify cause:	☐ I ☐ II ☐ III-a ☐ III-b ☐ IV-a ☐ IV-b ☐ V	Nerve(s) affected:
Postoperative death ☐ NO ☐ YES , specify cause: ☐ Bleeding ☐ Other: specify: ☐ Unknown cause	☐ V	When? postop day ..... Autopsy performed?: Findings

Was there an unscheduled DELAY of postoperative chemotherapy regimen? ☐ **NO** / ☐ **YES** → Delay in number of days: .....

Was this delay of postoperative chemotherapy *due to surgery*? ☐ **NO** / ☐ **YES** → **Cause:** .....

FIGURE 2. (Continued).

International Neuroblastoma Surgical Report Form (INSRF)

Clavien-Dindo Classification* of Surgical Complications

Grade I:	***Any deviation from the normal postoperative course*** *without the need for pharmacological treatment or surgical, endoscopic and radiological interventions. Acceptable therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics and electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside.*
Grade II:	*Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusions and total parenteral nutrition are also included.*
Grade III:	***Requiring surgical, endoscopic or radiological intervention***
Grade III-a:	*Intervention not under general anesthesia*
Grade III-b:	*Intervention under general anesthesia*
Grade IV:	*Life-threatening complication (including CNS complications)° **requiring IC/ICU-management***
Grade IV-a:	*Single organ dysfunction (including dialysis)*
Grade IV-b:	*Multi organ dysfunction*
Grade V:	***Death*** *of a patient*
Suffix 'd':	*If the patient suffers from a complication at the time of discharge. The suffix 'd' (for **'disability'**) is added to the respective grade of complication. This label indicates **the need for a follow-up** to fully evaluate the complication.*

°brain hemorrhage, ischemic stroke, subarrachnoidal bleeding, but excluding transient ischemic attacks (TIA); IC: intermediate care; ICU: intensive care unit

*Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–213
Clavien PA, Barkun J, de Oliveira ML et al. The Clavien-Dindo Classification of Surgical Complications. Five-Year Experience. Ann Surg 2009;250:187-196

FIGURE 2. (Continued).

surgical resection is an important part in the multimodal treatment protocols.[17,18]

In high-risk NBL and especially in case of distant metastatic disease, the role of surgical resection remains an unsolved issue even after more than 25 years of debate, with many authors favoring complete or gross total resection of the primary tumor[10,11,19–24] – whereas other authors question the role of aggressive surgical resection for high-risk NBL.[9,11,12,25] The reasons for these contradictory conclusions are linked to differences in protocols, especially indication, dose and field of adjuvant radiotherapy,[26] but also to the subjective appraisal of the completeness of resection, which relies predominantly on the surgeon's report. The assessment of the postoperative residue on imaging is not standardized and differently taken into account across the cooperative protocols.[19,25,27]

Postoperative irradiation has an important role in the multimodal treatment of high-risk NBL but is implicated in numerous late toxicities, including impairment in musculoskeletal growth, fertility, cardiopulmonary function and endocrinopathies, bladder dysfunction poor psychosocial health, and secondary malignancies.[24] The new SIOPEN HR-NBL2 protocol will randomize patients with macroscopic residual disease to receive a radiation boost of 36 Gray on postoperative residue, in addition to the baseline irradiation field of 21 Gray (depending on the preoperative tumor volume) (unpublished data). The patient will be considered to have no macroscopic residue at the time of radiotherapy if, cumulatively:

- the postoperative magnetic resonance imaging (or computed tomography scan, if no magnetic resonance imaging available) shows no definite residual tumor and
- the postoperative metaiodobenzylguanidine scan shows no residual tumor and
- the surgical report mentions a complete or minimal residual resection ($<5\,cm^3$ residual tumor remaining, according to international consensus (unpublished data) agreed upon during joint meetings with the surgeons and oncologists of the SIOPEN, COG, and GPOH surgical committees (Fig. 2).

Postoperative treatment will; therefore, rely on the surgeon's estimation and image-based description of the residue.

A recent analysis of the COG A3973 data did not show a statistically significant difference in outcomes based on the extent of prophylactic lymph node irradiation, regardless of the degree of surgical resection.[24] Although awaiting the results of the COG phase 3 trial ANBL0532, lowering the volume of postoperative irradiation and adapting an eventual boost on postoperative residue may also become part of upcoming COG NBL trials.[24] (unpublished data, personal communication).

Adequate documentation by the surgeon of the extent of surgical resection and of the volume and localization of postoperative residue, will; therefore, become essential and will need to rely on uniform, structured reporting, guided by clear-cut, unequivocal definitions.[12]

Recent analysis of 220 patients in the COG A3973 study (evaluating the impact of extent of primary tumor resection on local progression and survival and the assessed concordance between clinical and central imaging review-based assessments of resection extent), revealed however an important discordance (37%) between the operating surgeon's assessment of the extent of resection and imaging-aided assessment.[19] This may be related to the pitfalls of narrative operative reports as their content is not standardized nor regulated and may therefore be of variable quality.[28,29] In cancer surgery, several authors have recently pointed out that narrative operative reports are seldom complete and may be of poor quality[29–34] suggesting the development and use of standardized operative reports, also known as synoptic operative reports (SORs). Electronic SORs have been developed and implemented with proven benefit and multiple studies proving a gain in time.[35] In addition, structured operative reporting may even be beneficial for surgical education.[36]

The first version of the INSRF presented here is not intended to be a SOR: it is at present a standardized surgical report form, conceived as a structured checklist for the uniform registration of important variables and relevant clinical information on the surgery of NBL and its immediate outcomes. The obligatory standardized registration of intra- and postoperative complications according to the Clavien-Dindo classification[14,15] will improve the quality of data and facilitate even more the international comparison of different surgical timings, approaches, extents of resection and their outcomes.[19]

As the INSRF incorporates standardized reporting of the preoperative post-chemotherapy IDRFs, it will also aid in the analysis of the role of pre- versus post-chemotherapy IDRFs and tumor volumes.[4,7,8,12,37,38]

Furthermore, the INSRF may be used as well for the reporting of surgical interventions of other neuroblastic tumors (ie. ganglioneuroblastoma, ganglioneuroma,. . .) – where there is also still controversy on the approach, extent, and timing of surgical treatment.[8,37]

After its use by the members of the core working party group, confirming the feasibility, user-friendliness, and completeness of the INSRF, next steps in this joint international collaboration will be the further implementation into clinical practice, by the members of the surgical committees of SIOPEN, COG, and GPOH, to collect feedback from the individual users and further study adherence to the form. Interested pediatric surgical oncologists from other continents are also kindly invited to join this project. Development of an electronic web-based INSRF is highly recommended to allow surgeons to fill out the form immediately after surgery, warranting adherence, and the quality of data. The inclusion of an automated reminder to the surgeon 30 days after the operation to complete the registration of postoperative complications will ensure, as it was demonstrated in adult SORs for cancer,[39] higher rates of essential data completeness, intra- and interobserver reliability and faster and more efficient data entry.

The INSRF is highly compatible with different treatment protocols for localized, intermediate, and high-risk NBL. Its systematic incorporation in the new upcoming international NBL protocols of all cooperative groups will allow better analysis and definition of the surgical strategy in NBL treatment and comparison of local control modalities between international and cooperative groups.

In conclusion, the INSRF is the first attempt towards a universal operative report form for the structured and uniform reporting of all NBL-related surgical procedures. By documenting important perioperative data and outcomes, the INSRF will facilitate the analysis of the surgical treatment of NBL.

ACKNOWLEDGMENTS

The authors wish to gratefully thank all members of the Surgical Committees of SIOPEN, COG, and GPOH for their active and fruitful collaboration on this subject in the past, present, and future. The authors also wish to thank all participating pediatric oncology centers and cooperative groups and societies, and all patients and their parents, for this important joint collaboration across all borders, that gave birth to the first standardized INSRF.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin*. 2019;69:7–34.
2. Spix C, Pastore G, Sankila R, et al. Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. *Eur J Cancer*. 2006;42:2081–2091.
3. Maris JM. Recent advances in neuroblastoma. *N Engl J Med*. 2010;362:2202–2211.
4. Brisse HJ, Blanc T, Schleiermacher G, et al. Radiogenomics of neuroblastomas: relationships between imaging phenotypes, tumor genomic profile and survival. *PLoS One*. 2017;12:e0185190.
5. Park JR, Bagatell R, Cohn SL, et al. Revisions to the international neuroblastoma response criteria: a consensus statement from the National Cancer Institute clinical trials planning meeting. *J Clin Oncol*. 2017;35:2580–2587.
6. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. *J Clin Oncol*. 2009;27:289–297.
7. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG task force report. *J Clin Oncol*. 2009;27:298–303.
8. Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. *Radiology*. 2011;261:243–257.
9. Mullassery D, Farrelly P, Losty PD. Does aggressive surgical resection improve survival in advanced stage 3 and 4 neuroblastoma? A systematic review and meta-analysis. *Pediatr Hematol Oncol*. 2014;31:703–716.
10. La Quaglia MP, Kushner BH, Heller G, et al. Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. *J Pediatr Surg*. 1994;29:1162–1166.
11. Newman EA, Abdessalam S, Aldrink JH, et al. Update on neuroblastoma. *J Pediatr Surg*. 2019;54:383–389.
12. Muhling J, Eberherr C, Muller Hocker J, et al. Vessel adherent growth represents a major challenge in the surgical resection of neuroblastoma and is associated with adverse outcome. *J Pediatr Surg*. 2019;54:2336–2342.
13. Couinaud C. Liver anatomy: portal (and suprahepatic) or biliary segmentation. *Dig Surg*. 1999;16:459–467.
14. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg*. 2004;240:205–213.
15. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg*. 2009;250:187–196.
16. Qureshi SS, Kembhavi S, Ramadwar M, et al. Outcome and morbidity of surgical resection of primary cervical and cervicothoracic neuroblastoma in children: a comparative analysis. *Pediatr Surg Int*. 2014;30:267–273.
17. De Bernardi B, Mosseri V, Rubie H, et al. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. *Br J Cancer*. 2008;99:1027–1033.
18. Fischer J, Pohl A, Volland R, et al. Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months. *BMC Cancer*. 2017;17:520.
19. von Allmen D, Davidoff AM, London WB, et al. Impact of extent of resection on local control and survival in patients from the COG A3973 study with high-risk neuroblastoma. *J Clin Oncol*. 2017;35:208–216.
20. Englum BR, Rialon KL, Speicher PJ, et al. Value of surgical resection in children with high-risk neuroblastoma. *Pediatr Blood Cancer*. 2015;62:1529–1535.
21. La Quaglia MP. The role of primary tumor resection in neuroblastoma: when and how much? *Pediatr Blood Cancer*. 2015;62:1516–1517.
22. Holmes K, Poetschger U, Sarnacki S, et al. The influence of surgical excision on survival in high-risk neuroblastoma revisited after introduction of ch14.18/CHO immunotherapy in the HR-NBL1/SIOPEN trial. *J Clin Oncol*. 2018;36(15_Suppl):10521–10521.

23. Ladenstein R, Poetschger U, Sarnacki S, et al. The influence of surgical excision on survival in high-risk neuroblastoma revisited after introduction of ch14.18/CHO immunotherapy in the HR-NBL1/SIOPEN trial. *Pediatr Blood Cancer*. 2018;65:S36–S37.
24. Braunstein SE, London WB, Kreissman SG, et al. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: a report from the COG A3973 study. *Pediatr Blood Cancer*. 2019;66:e27736.
25. Simon T, Häberle B, Hero B, et al. Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. *J Clin Oncol*. 2013;31:752–758.
26. Stenman J, Herold N, Svensson PJ, et al. Improved local control by extensive surgery in high-risk neuroblastoma may be dependent on adjuvant radiotherapy. *J Clin Oncol*. 2017;35:1965–1966.
27. Holmes K, Sarnacki S, Poetschger U, et al. Influence of surgical excision on survival of patients with high risk neuroblastoma. Report from study 1 of Siop Europe (SIOPEN). *Pediatr Blood Cancer*. 2013;60:S3–S31.
28. Stewart L, Hunter JG, Wetter A, et al. Operative reports: form and function. *Arch Surg*. 2010;145:865–871.
29. Wiebe ME, Sandhu L, Takata JL, et al. Quality of narrative operative reports in pancreatic surgery. *Can J Surg*. 2013;56:E121–E127.
30. Donahoe L, Bennett S, Temple W, et al. Completeness of dictated operative reports in breast cancer–the case for synoptic reporting. *J Surg Oncol*. 2012;106:79–83.
31. Schneider L, Shargall Y, Schieman C, et al. Design of a consensus-derived synoptic operative report for lung cancer surgery. *Ann Thorac Surg*. 2014;97:1163–1168.
32. Maniar RL, Hochman DJ, Wirtzfeld DA, et al. Documentation of quality of care data for colon cancer surgery: comparison of synoptic and dictated operative reports. *Ann Surg Oncol*. 2014;21:3592–3597.
33. Edhemovic I, Temple WJ, de Gara CJ, et al. The computer synoptic operative report–a leap forward in the science of surgery. *Ann Surg Oncol*. 2004;11:941–947.
34. Maniar RL, Sytnik P, Wirtzfeld DA, et al. Synoptic operative reports enhance documentation of best practices for rectal cancer. *J Surg Oncol*. 2015;112:555–560.
35. Park J, Pillarisetty VG, Brennan MF, et al. Electronic synoptic operative reporting: assessing the reliability and completeness of synoptic reports for pancreatic resection. *J Am Coll Surg*. 2010;211:308–315.
36. Gur I, Gur D, Recabaren JA. The computerized synoptic operative report: a novel tool in surgical residency education. *Arch Surg*. 2012;147:71–74.
37. Irtan S, Brisse HJ, Minard-Colin V, et al. Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection. *Pediatr Blood Cancer*. 2015;62:1543–1549.
38. Avanzini S, Pio L, Erminio G, et al. Image-defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy-induced variation, and impact on surgical outcomes. *Pediatr Blood Cancer*. 2017;64:e26605.
39. Cundy TP, Kirby CP, Kirby ML. Synoptic operative reports for quality improvement in pediatric cancer care. *Pediatr Blood Cancer*. 2018;65:e27238